Sai Life Sciences, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has started the new financial year on a high note. The company has reported consolidated revenue from operations of INR 496 crore for the quarter ended 30 June 2025 (Q1 FY26), led by strong performance in the CDMO segment.
Sai Life Sciences Q1 FY26 Results– Financial Highlights
- Revenue from Operations: INR 496 crore, up 77% YoY (Q1 FY25: INR 280 crore)
- CDMO revenue: INR 314 crore, up 113% YoY
- CRO (Discovery) revenue: INR 182 crore, up 38% YoY
- EBITDA: INR 125 crore, up 305% YoY (Q1 FY25: INR 31 crore)
- EBITDA Margin: 25% vs. 11% in Q1 FY25
- Profit After Tax (PAT): INR 60 crore, up 448% YoY compared to a loss of INR 13 crore in Q1 FY25
- PAT Margin: 12% vs. -5% in Q1 FY25
- Operational Drivers
- Strong growth in the CDMO segment from deeper global client engagements
- Margin improvement driven by operating leverage, scale efficiencies, and productivity gains
- Expanded manufacturing and R&D capabilities to support complex and emerging drug modalities
Strategic Investments and Infrastructure Growth
In line with its long-term growth strategy, Sai Life Sciences invested INR 134 crore in capital expenditure during the quarter. Key developments included:
- Capacity Expansion: Commenced commercial operations at Bidar Unit IV (PB-11 Phase II), adding approximately 91 KL of capacity and taking total manufacturing capacity to around 700 KL. Work has begun to add another 200 KL capacity at the same site, targeted for completion by Q3 FY27.
- R&D Strengthening: Inaugurated a Peptide Research Center at the Hyderabad R&D campus to bolster complex peptide and emerging modality capabilities.
- Discovery Infrastructure: Opened a new 10,300 sq. ft. Biology facility with multiple laboratories to enhance integrated discovery offerings.
- Medicinal Chemistry Expansion: Construction underway for a new block with 200 fume hoods.
- Process R&D Growth: Broke ground for a new Process R&D Block at Unit 2 Hyderabad, nearly doubling PRD capacity and adding capabilities in early-phase peptide development and clinical formulations.
- Talent Onboarding: Hired 253 scientists and technical staff to support scaling operations.
The company also continued to reinforce its sustainability and compliance credentials, launching the “GoGreen Plus” logistics initiative with DHL, completing 11 client and regulatory audits across sites, and maintaining an unblemished record in global regulatory inspections.
Management Commentary
Managing Director & CEO, Krishna Kanumuri, said:
“We have begun FY26 well, with good performance across our Discovery, Development and Commercial Manufacturing businesses. This is a reflection of the growing trust and deeper engagement we have with our global pharma clients, who are anchoring us through macroeconomic uncertainty and industry cycles.
As the nature of innovation in drug development evolves, we are proactively investing in infrastructure and scientific depth to support complex and emerging modalities. These are deliberate steps in our journey to be the partner of choice for advancing innovation in complex science.”
Chief Financial Officer, Siva Chittor, added:
“Total revenue for the quarter stood at INR 496 crore, up 77% YoY, led by 113% growth in our CDMO segment and a 38% rise in Discovery revenues. We recorded EBITDA of INR 125 crore, with margins expanding to 25%, driven by operating leverage, scale efficiencies, and improved productivity. Our capex investments this quarter are aimed at strengthening capabilities in peptides, antibody-drug conjugates (ADCs), and oligonucleotides. We remain optimistic about sustaining this growth trajectory.”
Sai Life Sciences Post-IPO Performance
Sai Life Sciences IPO in December 2024 was a super hit, with 10.3x subscription and listed at INR 764.65, a 39.28% premium over the issue price of INR 549. The issue reached an all-time high of INR 846.3 per share on 30 July 2025, a return of 54.15% from the allotment price of INR 549 per share. However, there is a correction of ~1.9% from the highest peak. Currently, it is trading at around INR 837 per share.
Industry Context and Outlook
The global CRDMO industry is expected to reach USD 303 billion by 2028, driven by increasing outsourcing in pharma R&D and manufacturing, especially in biologics, peptides and other new modalities. The Indian CRDMO sector is expected to grow at a 14% CAGR between 2023 and 2028 due to cost advantage and global quality standards.
With Sai Life Sciences Q1 FY26 numbers reflecting strong momentum, the company’s ongoing investments position it to achieve its target of 15–20% long-term revenue CAGR and 28–30% EBITDA margins over the next 2–3 years. Its 25+ years of experience, relationships with 18 of the world’s top 25 pharma companies, and integrated capabilities across discovery, development, and manufacturing give it a competitive edge in capturing market share.
About Sai Life Sciences
Founded in 1999 and headquartered in Hyderabad, India, Sai Life Sciences is a global CRDMO serving innovator pharma and biotech companies. Its integrated offerings span medicinal chemistry, process development, manufacturing and advanced technology platforms. The company has world-class R&D and manufacturing facilities in India, the UK and the USA with a strong focus on science, quality and sustainability.
With the robust Sai Life Sciences Q1 FY26 performance setting the tone, the company looks set to accelerate growth while deepening its position as a trusted global partner in pharmaceutical innovation.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription, stay tuned to IPO Central.